Overview

* IDEXX ( IDXX ) Q3 revenue grows 13%, beating analyst expectations

* EPS for Q3 increased 21% to $3.40

Outlook

* IDEXX ( IDXX ) raises 2025 revenue guidance to $4.27 bln - $4.3 bln

* Company raises 2025 EPS outlook to $12.81 - $13.01

* IDEXX ( IDXX ) sees 2025 organic revenue growth of 8.8% - 9.5%

Result Drivers

* INNOVATION STRATEGY - IDEXX ( IDXX ) attributes strong Q3 revenue growth to execution of its innovation-driven strategy, including over 1,700 IDEXX ( IDXX ) inVue Dx placements

* CAG DIAGNOSTICS - CAG Diagnostics recurring revenue grew 11% as reported, driven by increased diagnostic frequency and easing clinical visit pressures in the U.S.

* OPERATING MARGIN EXPANSION - Operating margin increased by 100 basis points, supported by productivity initiatives and volume gains in Reference Labs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $1.10 $1.07

Revenue bln bln (10

Analysts

)

Q3 EPS $3.40

Q3 Gross 61.80%

Margin

Q3 EBIT 32.10%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for IDEXX Laboratories Inc ( IDXX ) is $720.00, about 12.6% above its October 31 closing price of $629.51

* The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 41 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)